BRIEF published on 06/12/2026 at 09:25, 3 months ago CS2009: A Potential Game-Changer in Immuno-Oncology Clinical Trials Immuno-oncology ASCO 2026 CS2009 Trispecific Antibody
BRIEF published on 06/12/2026 at 09:25, 3 months ago CS2009 : Un tournant potentiel en immuno-oncologie Essais Cliniques Immuno-oncologie ASCO 2026 CS2009 Anticorps Trispécifique
PRESS RELEASE published on 06/12/2026 at 09:20, 3 months ago CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights Clinical datasets presented at ASCO 2026 validate trispecific mechanism of CS2009 in immuno-oncology, showing potential for long-term survival benefits and favorable tolerability Immuno-oncology ASCO 2026 CS2009 Trispecific Mechanism Clinical Datasets
BRIEF published on 06/12/2026 at 09:07, 3 months ago CS2009 at ASCO 2026: Clinical Potential and Safety Profile Immuno-oncology ASCO 2026 CS2009 Trispecific Antibody VEGF Toxicity
BRIEF published on 06/12/2026 at 09:07, 3 months ago CS2009 à l'ASCO 2026 : Potentiel clinique et profil de sécurité Immuno-oncologie ASCO 2026 CS2009 Anticorps Trispécifique Toxicité Du VEGF
PRESS RELEASE published on 06/12/2026 at 09:02, 3 months ago CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights Clinical datasets presented at ASCO 2026 validate trispecific synergistic mechanism of CS2009 for next-gen immuno-oncology backbone therapy Immuno-oncology ASCO 2026 CS2009 Trispecific Mechanism Clinical Datasets
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
